ADC Therapeutics (ADCT) Receivables (2021 - 2026)

ADC Therapeutics has disclosed Receivables across 6 years of filings, most recently posting $31.0 million for Q1 2026.

• Receivables for Q1 2026 came in at $31.0 million, down 2.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.0 million (down 2.26% YoY), and the FY2025 annual result was $29.1 million, up 43.32% from the prior year.
• Receivables came in at $31.0 million for Q1 2026 at ADC Therapeutics, up from $29.1 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $73.8 million in Q4 2022 to a low of $20.3 million in Q4 2024.
• The 5-year median for Receivables is $25.2 million (2023), against an average of $30.0 million.
• Across the five-year window, Receivables jumped 137.93% in 2022 and tumbled 65.87% in 2023, its largest moves.
• ADC Therapeutics' Receivables stood at $73.8 million in 2022, then tumbled by 65.87% to $25.2 million in 2023, then dropped by 19.32% to $20.3 million in 2024, then surged by 43.32% to $29.1 million in 2025, then advanced by 6.62% to $31.0 million in 2026.
• The last three Receivables figures came in at $31.0 million (Q1 2026), $29.1 million (Q4 2025), and $22.9 million (Q3 2025), per Business Quant data.